Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.

PMID: 32140889
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2020
Reference: Invest New Drugs. 2020 Oct;38(5):1570-1579. doi: 10.1007/s10637-020-00910-9. Epub 2020 Mar 5.
Impact factor: 3.525
Publication type: Paper in international publication
Authors: Rodon, Jordi, Capper, David, Guba, Susan C, Wang, Shuaicheng, Wick, Antje, Desjardins, Annick, Suarez, Cristina, Forsyth, Peter, Gueorguieva, Ivelina, Burkholder, Tiana et al.
DOI: 10.1007/s10637-020-00910-9

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.

PMID: 32140889
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2020
Reference: Invest New Drugs. 2020 Oct;38(5):1570-1579. doi: 10.1007/s10637-020-00910-9. Epub 2020 Mar 5.
Impact factor:
Publication type: Paper in international publication
Authors: Burkholder, Tiana; Capper, David; Cleverly, Ann Louise; Desjardins, Annick; Estrem, Shawn T; Forsyth, Peter; Guba, Susan C; Gueorguieva, Ivelina; Lahn, Michael M; Rodon, Jordi et al.
DOI: 10.1007/s10637-020-00910-9

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.

PMID: 33138866
Journal: BREAST CANCER RESEARCH
Year: 2020
Reference: Breast Cancer Res. 2020 Nov 2;22(1):120. doi: 10.1186/s13058-020-01354-y.
Impact factor: 4.988
Publication type: Paper in international publication
Authors: Villagrasa, Patricia, Li, Yisheng, Savoie, Jennifer, Xu, Zhan, Arteaga, Carlos L, Krop, Ian E, Solit, David B, Mills, Gordon B, Cantley, Lewis C, Winer, Eric P et al.
DOI: 10.1186/s13058-020-01354-y

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.

PMID: 33138866
Journal: BREAST CANCER RESEARCH
Year: 2020
Reference: Breast Cancer Res. 2020 Nov 2;22(1):120. doi: 10.1186/s13058-020-01354-y.
Impact factor:
Publication type: Paper in international publication
Authors: Arteaga, Carlos L; Barroso-Sousa, Romualdo; Bermejo, Begona; Cantley, Lewis C; Celiz, Pamela; Ciruelos, Eva; Garrido-Castro, Ana C; Gavila, Joaquin; Guo, Hao; Krop, Ian E et al.
DOI: 10.1186/s13058-020-01354-y

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

PMID: 32661186
Journal: ESMO Open
Year: 2020
Reference: ESMO Open. 2020 Jul;5(4). pii: esmoopen-2020-000673. doi: 10.1136/esmoopen-2020-000673.
Impact factor: 5.329
Publication type: Paper in international publication
Authors: Wen, Patrick Yung, Rodon, Jordi A, Mason, Warren, Beck, Joseph T, DeGroot, John, Donnet, Valerie, Mills, David, El-Hashimy, Mona, Rosenthal, Mark et al.
DOI: 10.1136/esmoopen-2020-000673

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

PMID: 32661186
Journal: ESMO Open
Year: 2020
Reference: ESMO Open. 2020 Jul;5(4). pii: esmoopen-2020-000673. doi: 10.1136/esmoopen-2020-000673.
Impact factor:
Publication type: Paper in international publication
Authors: Beck, Joseph T; DeGroot, John; Donnet, Valerie; El-Hashimy, Mona; Mason, Warren; Mills, David; Rodon, Jordi A; Rosenthal, Mark; Wen, Patrick Yung et al.
DOI: 10.1136/esmoopen-2020-000673

Phase I study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts.

PMID: 31778267
Journal: CANCER SCIENCE
Year: 2020
Reference: Cancer Sci. 2020 Feb;111(2):536-547. doi: 10.1111/cas.14254. Epub 2019 Dec 30.
Impact factor: 4.966
Publication type: Paper in international publication
Authors: Bang, Yung-Jue, Su, Wu-Chou, Schuler, Martin, Nam, Do-Hyun, Lim, Wan Teck, Bauer, Todd M, Azaro, Analia, Poon, Ronnie Tung Ping, Hong, David, Lin, Chia-Chi et al.
DOI: 10.1111/cas.14254

Phase I study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts.

PMID: 31778267
Journal: CANCER SCIENCE
Year: 2020
Reference: Cancer Sci. 2020 Feb;111(2):536-547. doi: 10.1111/cas.14254. Epub 2019 Dec 30.
Impact factor:
Publication type: Paper in international publication
Authors: Akimov, Mikhail; Azaro, Analia; Bang, Yung-Jue; Bauer, Todd M; Ghebremariam, Samson; Giovannini, Monica; Hong, David; Lim, Wan Teck; Lin, Chia-Chi; Ma, Brigette et al.
DOI: 10.1111/cas.14254

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.

PMID: 32240793
Journal: ANNALS OF ONCOLOGY
Year: 2020
Reference: Ann Oncol. 2020 Jun;31(6):780-788. doi: 10.1016/j.annonc.2020.03.294. Epub 2020 Mar 30.
Impact factor:
Publication type: Paper in international publication
Authors: Arias, M; Aronchik, I; Brana, I; De Alvaro, J; Di Martino, J; Doger, B; Ferrero, O; Filvaroff, E H; Hanna, B; Hernandez-Guerrero, T et al.
DOI: 10.1016/j.annonc.2020.03.294

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma.

PMID: 32327472
Journal: CLINICAL CANCER RESEARCH
Year: 2020
Reference: Clin Cancer Res. 2020 Jul 15;26(14):3546-3556. doi: 10.1158/1078-0432.CCR-19-3239. Epub 2020 Apr 23.
Impact factor: 10.107
Publication type: Paper in international publication
Authors: Gordon, Leo I, Kaplan, Jason B, Popat, Rakesh, Burris, Howard A, Ferrari, Silvia, Madan, Sumit, Patel, Manish R, Gritti, Giuseppe, El-Sharkawi, Dima, Chau, Ian et al.
DOI: 10.1158/1078-0432.CCR-19-3239

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma.

PMID: 32327472
Journal: CLINICAL CANCER RESEARCH
Year: 2020
Reference: Clin Cancer Res. 2020 Jul 15;26(14):3546-3556. doi: 10.1158/1078-0432.CCR-19-3239. Epub 2020 Apr 23.
Impact factor:
Publication type: Paper in international publication
Authors: Bosch, Francesc; Burris, Howard A; Carpio, Cecilia; Chau, Ian; El-Sharkawi, Dima; Ferrari, Silvia; Gordon, Leo I; Gritti, Giuseppe; Iyer, Swami; Kaplan, Jason B et al.
DOI: 10.1158/1078-0432.CCR-19-3239

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.

PMID: 31540980
Journal: CLINICAL CANCER RESEARCH
Year: 2020
Reference: Clin Cancer Res. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965. Epub 2019 Sep 20.
Impact factor: 10.107
Publication type: Paper in international publication
Authors: Gerber, David E, Infante, Jeffrey R, Gordon, Michael S, Goldberg, Sarah B, Burris, Howard A, Martin, Miguel, Felip, Enriqueta, Martinez Garcia, Maria, Schiller, Joan H, Spigel, David R et al.
DOI: 10.1158/1078-0432.CCR-18-3965

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.

PMID: 31540980
Journal: CLINICAL CANCER RESEARCH
Year: 2020
Reference: Clin Cancer Res. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965. Epub 2019 Sep 20.
Impact factor:
Publication type: Paper in international publication
Authors: Burris, Howard A; Choi, Younjeong; Cordova, Julie; Dere, Randall C; Felip, Enriqueta; Gerber, David E; Goldberg, Sarah B; Gordon, Michael S; Humke, Eric W; Infante, Jeffrey R et al.
DOI: 10.1158/1078-0432.CCR-18-3965

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

PMID: 31395751
Journal: ONCOLOGIST
Year: 2020
Reference: Oncologist. 2020 Jan;25(1):e160-e169. doi: 10.1634/theoncologist.2019-0297. Epub 2019 Aug 8.
Impact factor: 5.025
Publication type: Paper in international publication
Authors: Rodon, Jordi, Janku, Filip, Lolkema, Martijn P, Stephenson, Joe J, Bedard, Philippe L, Schuler, Martin, Sessa, Cristiana, LoRusso, Patricia, Thomas, Michael, Maacke, Heiko et al.
DOI: 10.1634/theoncologist.2019-0297

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

PMID: 31395751
Journal: ONCOLOGIST
Year: 2020
Reference: Oncologist. 2020 Jan;25(1):e160-e169. doi: 10.1634/theoncologist.2019-0297. Epub 2019 Aug 8.
Impact factor:
Publication type: Paper in international publication
Authors: Bardia, Aditya; Bedard, Philippe L; Evans, Helen; Gounder, Mrinal; Janku, Filip; Lolkema, Martijn P; LoRusso, Patricia; Maacke, Heiko; Rodon, Jordi; Schuler, Martin et al.
DOI: 10.1634/theoncologist.2019-0297

Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results.

PMID: 33246428
Journal: BMC CANCER
Year: 2020
Reference: BMC Cancer. 2020 Nov 27;20(1):1164. doi: 10.1186/s12885-020-07661-z.
Impact factor:
Publication type: Paper in international publication
Authors: Alonso-Orduna, Vicente; Aranda, Enrique; Biondo, Sebastiano; Capdevila, Jaume; Escudero, Pilar; Gallego, Javier; Garcia-Paredes, Beatriz; Gomez-Espana, Auxiliadora; Gravalos, Cristina; Lopez, Carlos et al.
DOI: 10.1186/s12885-020-07661-z

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.

PMID: 32554315
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2020
Reference: Eur J Cancer. 2020 Aug;135:89-97. doi: 10.1016/j.ejca.2020.04.031. Epub 2020 Jun 15.
Impact factor: 7.275
Publication type: Paper in international publication
Authors: Amoroso, Loredana, Castel, Victoria, Bisogno, Gianni, Casanova, Michela, Marquez-Vega, Catalina, Chisholm, Julia C, Doz, Francois, Moreno, Lucas, Ruggiero, Antonio, Gerber, Nicolas U et al.
DOI: 10.1016/j.ejca.2020.04.031

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.

PMID: 32554315
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2020
Reference: Eur J Cancer. 2020 Aug;135:89-97. doi: 10.1016/j.ejca.2020.04.031. Epub 2020 Jun 15.
Impact factor:
Publication type: Paper in international publication
Authors: Amoroso, Loredana; Bisogno, Gianni; Casanova, Michela; Castel, Victoria; Chen, Nianhang; Chisholm, Julia C; Doz, Francois; Fagioli, Franca; Gerber, Nicolas U; Hingorani, Pooja et al.
DOI: 10.1016/j.ejca.2020.04.031

Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).

PMID: 32578279
Journal: EUROPEAN JOURNAL OF CANCER CARE
Year: 2020
Reference: Eur J Cancer Care (Engl). 2020 Jul;29(4):e13253. doi: 10.1111/ecc.13253. Epub 2020 Jun 23.
Impact factor: 2.161
Publication type: Paper in international publication
Authors: Ciruelos, Eva M, Montano, Alvaro, Rodriguez, Cesar A, Gonzalez-Flores, Encarnacion, Lluch, Ana, Garrigos, Laia, Quiroga, Vanesa, Anton, Antonio, Malon, Diego, Chacon, Jose I et al.
DOI: 10.1111/ecc.13253

Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).

PMID: 32578279
Journal: EUROPEAN JOURNAL OF CANCER CARE
Year: 2020
Reference: Eur J Cancer Care (Engl). 2020 Jul;29(4):e13253. doi: 10.1111/ecc.13253. Epub 2020 Jun 23.
Impact factor:
Publication type: Paper in international publication
Authors: Amigo, Yolanda; Anton, Antonio; Carrasco, Eva; Casas, Ana; Casas, Maribel; Chacon, Jose I; Ciruelos, Eva M; Echarri, Maria J; Garrigos, Laia; Gonzalez-Cortijo, Lucia et al.
DOI: 10.1111/ecc.13253

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours.

PMID: 33262202
Journal: ESMO Open
Year: 2020
Reference: ESMO Open. 2020 Dec;5(6). pii: esmoopen-2020-001081. doi: 10.1136/esmoopen-2020-001081.
Impact factor:
Publication type: Paper in international publication
Authors: Arkenau, Hendrik-Tobias; Azaro, Analia; Bono, Petri; Curigliano, Giuseppe; Garratt, Chris; Hakulinen, Pasi; Ikonen, Tarja; Italiano, Antoine; Kristeleit, Rebecca S; Lassen, Ulrik et al.
DOI: 10.1136/esmoopen-2020-001081

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

PMID: 31959756
Journal: Nature Communications
Year: 2020
Reference: Nat Commun. 2020 Jan 20;11(1):385. doi: 10.1038/s41467-019-14111-3.
Impact factor: 12.121
Publication type: Paper in international publication
Authors: Braso-Maristany, Fara, Griguolo, Gaia, Pascual, Tomas, Pare, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begona, Oliveira, Mafalda, Morales, Serafin, Martinez, Noelia et al.
DOI: 10.1038/s41467-019-14111-3

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

PMID: 31959756
Journal: Nature Communications
Year: 2020
Reference: Nat Commun. 2020 Jan 20;11(1):385. doi: 10.1038/s41467-019-14111-3.
Impact factor:
Publication type: Paper in international publication
Authors: Adamo, Barbara; Alarcon, Jesus; Bermejo, Begona; Braso-Maristany, Fara; Chic, Nuria; Ciruelos, Eva; Cortes, Javier; Galvan, Patricia; Garau, Isabel; Gomis, Roger R et al.
DOI: 10.1038/s41467-019-14111-3

Phenotyping occupational asthma caused by acrylates in a multicentre cohort study.

PMID: 31678289
Journal: Journal of Allergy and Clinical Immunology-In Practice
Year: 2020
Reference: J Allergy Clin Immunol Pract. 2020 Mar;8(3):971-979.e1. doi: 10.1016/j.jaip.2019.10.017. Epub 2019 Oct 31.
Impact factor: 7.574
Publication type: Paper in international publication
Authors: Lindstrom, Irmeli, Sastre, Joaquin, Walusiak-Skorupa, Jolanta, Munoz, Xavier, Talini, Donatella, Klusackova, Pavlina, Moore, Vicky, Merget, Rolf, Svanes, Cecilie, Mason, Paola et al.
DOI: 10.1016/j.jaip.2019.10.017

Publications

Publications searcher

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

Phase I study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts.

Phase I study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts.

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma.

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma.

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results.

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.

Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).

Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours.

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

Phenotyping occupational asthma caused by acrylates in a multicentre cohort study.

Patronage:

Collaborating:

Accreditations: